NEW YORK--(BUSINESS WIRE)--The overhanging risk of generic competition to Copaxone could prompt material top-line and profit losses at Teva Pharmaceutical Industries Ltd., according to Fitch Ratings.

FDA is widely known to be considering the approval of a generic version of Teva Pharmaceutical’s (NYSE:TEVA) blockbuster drug for multiple sclerosis, Copaxone. The patents covering Copaxone for its ...

Jul. 4—MORGANTOWN — The tangled world of generic pharmaceuticals took another twist last week, as Mylan Pharmaceuticals filed suit in federal court against Israel-based Teva, alleging Teva illegally ...

Teva’s fight to keep generic Copaxone off the market hit a snag Friday when the Supreme Court said it would not allow an injunction to go forward while the drugmaker waited for the appeals process to ...

TEL AVIV, July 14 (Reuters) - There will not be any generic version of Teva Pharmaceutical Industries' multiple sclerosis drug Copaxone before 2014, the company's president and chief executive said in ...

Israel-based Teva Pharmaceutical is one of the largest global generic drug manufacturers, with a significant presence in the United States and in Western Europe. Generic drug manufacturers with large ...

A generic version of multiple sclerosis drug Copaxone was introduced in 2015, but it has done little to lower drug costs for MS patients, NPR reported. Yearly costs for MS drugs can run as high as $50 ...

Teva Pharmaceutical is facing down plenty of lawsuits. Now, one of its chief rivals in the generics field is adding another case to Teva's plate. Mylan, which has merged with Pfizer's Upjohn to form ...

Teva’s push to keep generic Copaxone off the market its over. Bloomberg reports the company lost its suit to keep generics at bay, just 10 days before the expiration of the branded MS drug’s patent.

Mylan has slashed its list price on generic Copaxone, and the move has industry watchers scratching their heads. According to Bernstein analyst Ronny Gal, the company has sunk its sticker to $1,900 ...

Sometimes, the approval of a new generic drug offers more hype than hope for patients' wallets, as people with multiple sclerosis know all too well. New research shows just how little the introduction ...